Chest
Original ResearchAspergillus Bronchitis in Cystic Fibrosis
Section snippets
Materials and Methods
The patients received diagnosis and treatment from 2002 to 2003 at the CF Center, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel (4 of 80 patients in this clinic) and Pediatric Regional Cystic Fibrosis Centre, St James’ and Seacroft University Hospitals, Leeds, UK (2 of 151 pediatric patients in this clinic). Specific IgE anti-A fumigatus were measured by enzyme-linked immunosorbent assay (Dr. Fooke Laboratories; Neuss, Germany) and were scored from 0 to 4: score 0, 0 to 0.34
Case 1
A 22-year-old man with CF (G524X/ΔF508) and pancreatic insufficiency (Table 1) presented after 6 months of clinical deterioration despite intensive physiotherapy, inhaled antibiotics, and several courses of treatment with IV antibiotics according to bacterial sensitivity. He had lost 5 kg of weight, from 54 to 49 kg, and showed decreased expiratory flow rates (FEV1, 32% of predicted). Breath sounds were wet with crackles over the lower lobes of both lung, but there were no wheezes. Sputum
Case 2
A 13-year-old boy with CF (3849 + 10kbC->T/ΔF508) and pancreatic sufficiency (Table 1) presented with a respiratory exacerbation with increased sputum production, weight loss, and decreased expiratory flow rates. Breath sounds were normal, with no crackles or wheezes. Sputum cultures grew P aeruginosa, M simiae, and A fumigatus. He was treated with oral ciprofloxacin and gentamicin inhalations and subsequently with IV antibiotics according to the sensitivity of the P aeruginosa culture. His
Case 3
A 15-year-old boy with CF (W1282X/ΔF508) and pancreatic insufficiency (Table 1) presented with increased sputum production, decreased expiratory flow rate, and weight loss. Breath sounds were reduced with a few dry crackles mainly in the left and right lower lobes. Sputum cultures grew P aeruginosa, M abscessus, and A fumigatus. There was no improvement in respiratory function tests or weight after treatment with IV antibiotics chosen according to the sensitivity profile of the P aeruginosa
Case 4
A 30-year-old woman with CF (W1282X/unknown), pancreatic sufficiency, and chronic sinusitis (Table 1) presented with increased cough and sputum production. No significant changes in expiratory flow rates or weight were observed. Lung examination revealed a few wet crackles in the left lung. IgE was 542 IU/mL; FEV1, 57% of predicted; ESR, 25 mm/h. Serum Aspergillus-specific IgE and skin-prick test results to A fumigatus were negative. Sputum culture grew A fumigatus, P aeruginosa, and B cepacia
Case 5
A 10-year-old boy, homozygous ΔF508 (Table 1), presented with a productive cough, severe exercise restriction, lethargy, and weight loss. Wheeze was not a feature. FEV1 fell from 79 to 47% of predicted over a 9-month period. Sputum samples were consistently positive for A fumigatus, and no other respiratory pathogens were identified. There was no improvement in clinical parameters or respiratory function with broad-spectrum IV antibiotics. Aspergillus-specific IgE was negative, while total IgE
Case 6
A 12-year-old boy (ΔF508\Y1898 + 1) [Table 1] presented with chest pain, breathlessness, a productive cough, and weight loss. FEV1 and FVC had fallen from 80 to 47% of predicted and 88 to 54% of predicted, respectively; and oxygen saturation decreased from 98 to 92% over a 3-month period. Sputum culture results were repeatedly positive for A fumigatus. Total IgE was 123 IU/mL, Aspergillus-specific IgE was negative, and eosinophil count remained normal. Aspergillus-precipitating antibodies
Discussion
In this report, six patients with CF and positive sputum culture findings for A fumigatus but not meeting criteria for ABPA had acute or subacute clinical deterioration. The patients did not respond to appropriate antibiotic treatment directed to microorganisms identified in sputum cultures, but responded over varying periods of time and degree to antifungal medications. All patients grew A fumigatus in sputum culture, but none met the criteria required for diagnosis of ABPA1 (Table 3).
References (18)
- et al.
A 12-year longitudinal study of Aspergillus sensitivity in cystic fibrosis patients
Chest
(1996) - et al.
Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Chest
(1999) - et al.
Purification of a major allergen, Asp f 2 binding to IgE in allergic bronchopulmonary aspergillosis, from culture filtrate of Aspergillus fumigatus
J Allergy Clin Immunol
(1997) - et al.
Allergic bronchopulmonary aspergillosis in cystic fibrosis
J Allergy Clin Immunol
(1984) - et al.
Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature
Chest
(2001) - et al.
Allergic bronchopulmonary aspergillosis in cystic fibrosis: state of the art; Cystic Fibrosis Foundation Consensus Conference
Clin Infect Dis
(2003) - et al.
Allergic bronchopulmonary mycosis complicating cystic fibrosis
Semin Respir Infect
(1992) - et al.
Evaluation of scoring system of the chest radiograph in cystic fibrosis: a collaborative study
AJR Am J Roentgenol
(1980) - et al.
Cystic fibrosis: scoring system with thin-section CT
Radiology
(1991)
Cited by (143)
Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues
2024, Journal of Cystic FibrosisPulmonary Aspergillosis in People with Cystic Fibrosis
2024, Seminars in Respiratory and Critical Care MedicineModel of Pulmonary Co-Infection of Aspergillus and Pseudomonas in Immunocompetent Mice
2023, Microbiology ResearchRespiratory Fungal Infections in Cystic Fibrosis: Diagnostic and Therapeutic Challenges
2023, Current Fungal Infection Reports
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
The authors have no conflicts of interest on this topic.